Tech Center 1600 • Art Units: 1643 1674
This examiner grants 64% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17596421 | METHODS OF PRODUCING AN ANTI-a4B7 ANTIBODY | Final Rejection | Takeda Pharmaceutical Company Limited |
| 18038101 | ENGINEERED T CELLS FOR EXPRESSION OF CHIMERIC ANITGEN RECEPTORS | Non-Final OA | The Regents of the University of California |
| 18138679 | TARGETING STROMA-CANCER INTERACTIONS IN CANCER | Non-Final OA | The Regents of the University of California |
| 17310279 | TARGETED DELIVERY OF IFN GAMMA USING ANTIBODY FUSION PROTEINS | Final Rejection | The Regents of the University of California |
| 17697632 | BISPECIFIC FC MOLECULES | Non-Final OA | Amgen Inc. |
| 17431276 | USE OF A STIMULATING AGENT TO ASSAY IMMUNE CELL POTENCY | Final Rejection | RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL |
| 17183904 | COMPOSITIONS COMPRISING IL6R ANTIBODIES FOR THE TREATMENT OF UVEITIS AND MACULAR EDEMA AND METHODS OF USING SAME | Non-Final OA | REGENERON PHARMACEUTICALS, INC. |
| 18177023 | TRANSFORMED NATURAL KILLER CELL | Non-Final OA | Purdue Research Foundation |
| 18080452 | HIF-1a MODULATORS AND USES THEREOF | Non-Final OA | Brown University |
| 18317797 | ENHANCED IMMUNE CELLS USING DUAL SHRNA AND COMPOSITION INCLUDING THE SAME | Non-Final OA | KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY |
| 18264604 | CHIMERIC ANTIGEN RECEPTOR WITH ENDOGENOUS PROTEIN MOLECULE REPLACING SINGLE DOMAIN ANTIBODY | Non-Final OA | ZHEJIANG UNIVERSITY |
| 18917836 | EFFECTOR CELLS AND USE THEREOF FOR ALLOGENEIC ADOPTIVE CELL THERAPIES IN SOLID TUMORS | Non-Final OA | FATE THERAPEUTICS, INC. |
| 17430331 | COMBINATION OF T-CELL THERAPY AND TARGETED THERAPY FOR TREATING THERAPY-RESISTANT MELANOMA WITH MUTATIONS IN THE BRAF GENE | Non-Final OA | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. |
| 18284209 | HUMANIZED ANTIBODIES AGAINST PAIRED HELICAL FILAMENT TAU AND USES THEREOF | Non-Final OA | Janssen Biotech, Inc. |
| 17290128 | PEPTIDES, COMPOSITIONS AND VACCINES FOR TREATMENT OF MICROSATELLITE INSTABLITY HYPERMUTATED TUMORS AND METHODS OF USE THEREOF | Non-Final OA | Icahn School of Medicine at Mount Sinai |
| 18038423 | COMPOSITIONS AND USES OF PSCA TARGETED CHIMERIC ANTIGEN RECEPTOR MODIFIED CELLS | Non-Final OA | City of Hope |
| 18201620 | USE OF ANTI-IL-27 ANTIBODIES | Non-Final OA | MSD INTERNATIONAL GMBH |
| 17264522 | IMMUNE MODIFYING PARTICLES FOR THE TREATMENT OF CANCER | Final Rejection | onCour Pharma, Inc. |
| 17290439 | HER2 S310F SPECIFIC ANTIGEN-BINDING MOLECULES | Final Rejection | Chugai Seiyaku Kabushiki Kaisha |
| 16978953 | ANTI-PD-1 VACCINE COMPOSITION | Non-Final OA | CONSERVATOIRE NATIONAL DES ARTS ET METIERS |
| 18248979 | ANTI-C-C CHEMOKINE RECEPTOR 8 (CCR8) ANTIBODIES AND METHODS OF USE THEREOF | Non-Final OA | Five Prime Therapeutics, Inc. |
| 17431041 | PRODUCING COMPOSITIONS COMPRISING TWO OR MORE ANTIBODIES | Non-Final OA | Merus N.V. |
| 16499144 | ERBB-2 TARGETING AGENT AND A BISPECIFIC ANTIBODY WITH ANTIGEN-BINDING SITES THAT BIND AN EPITOPE ON AN EXTRACELLULAR PART OF ERB-2 AND ERBB-3, FOR TREATMENT OF AN INDIVIDUAL WITH AN ERBB-2, ERBB-2/ERBB-3 POSITIVE TUMOUR | Final Rejection | Merus N.V. |
| 18218535 | Sialylated Glycoproteins | Non-Final OA | Momenta Pharmaceuticals, Inc. |
| 17599468 | COMPOSITIONS AND METHODS FOR PREPARING T CELL COMPOSITIONS AND USES THEREOF | Final Rejection | BIONTECH US INC. |
| 18266340 | PRAME BINDING MOLECULE | Non-Final OA | MIE UNIVERSITY |
| 18266435 | METHODS FOR GENERATING HEMATOPOIETIC STEM CELLS AND COMPOSITIONS THEREOF | Non-Final OA | GARUDA THERAPEUTICS, INC. |
| 18042276 | CATIONIC NANOPARTICLE ADJUVANTS | Non-Final OA | Rasheid SMITH |
| 18041770 | RECOMBINANT IMMUNOTOXIN COMPRISING A RIBOTOXIN OR RNASE | Final Rejection | ATB Therapeutics |
| 17258529 | Cyclic Single-Chain Antibody | Non-Final OA | NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITY |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy